Clinical Study of Su Fei He Ji Combined with Anlotinib in the Treatment of Advanced,Refractory Non-Small Cell Lung Cancer Patients with Phlegm Stasis and Lung Obstruction
- VernacularTitle:中药肃肺合剂联合安罗替尼治疗晚期后线痰瘀阻肺型非小细胞肺癌患者的临床研究
- Author:
Wenyue ZHAO
1
;
Chencen ZHANG
1
;
Lidong GAO
1
;
Kemiao YUAN
1
;
Jiayu ZHOU
1
;
Chunhui JIN
1
;
Baonan ZHANG
1
Author Information
- Publication Type:Journal Article
- Keywords: Advanced non-small cell lung cancer; Anlotinib hydrochloride; Su Fei He Ji; Phlegm stasis obstructing lung type
- From: World Science and Technology-Modernization of Traditional Chinese Medicine 2025;27(4):1113-1119
- CountryChina
- Language:Chinese
- Abstract: Objective To evaluate the effectiveness and safety of Su Fei He Ji combined with anlotinib hydrochloride in the treatment of refractory advanced non-small cell lung cancer(NSCLC)patients presenting with phlegm stasis obstructing lung type.Methods Thirty-nine patients with advanced NSCLC were randomly assigned to either a control group(19 patients)or an experimental group(20 patients).The control group received treatment with anlotinib alone,while the experimental group received an additional oral administration of Su Fei He Ji.A comparative analysis was conducted between the two groups based on various parameters including short-term objective therapeutic efficacy,progression-free survival,TCM syndrome scores,KPS scores,weight changes,related tumor markers,incidence of adverse reactions,and variations in plasma concentrations of anlotinib.Results Following treatment,the objective response rate was 5%and the disease control rate was 85%in the experimental group,while the control group showed an objective response rate of 0%and a disease control rate of 78.95%.No statistically significant difference was observed in short-term objective efficacy between the two groups(P>0.05).Notably,the experimental group exhibited a significant improvement compared to the control group in various aspects,including TCM syndrome scores and KPS scores(P<0.05).Conversely,no significant differences were observed in weight changes or the reduction levels of other tumor markers(CEA,SCC,CA125,CA199,CYFRA21-1)(P>0.05).Moreover,the incidence of fatigue was notably lower in the experimental group(P<0.05),while no statistical difference was evident in the occurrence of other adverse reactions,such as hypertension,rash,and bleeding,between the two groups(P>0.05).It is important to highlight that there was no statistically significant variance in plasma concentrations between the groups(P>0.05),and no significant correlation was identified between plasma concentrations and the incidence of adverse reactions(P>0.05).Conclusion The combination of Su Fei He Ji and anlotinib hydrochloride effectively improves clinical symptoms and quality of life,and reduces adverse reactions in advanced NSCLC patients.This is achieved without affecting the plasma concentrations of anlotinib.
